×
ADVERTISEMENT

NOVEMBER 26, 2024

FDA Grants Accelerated Approval to Ziihera for Some People With Biliary Tract Cancer


Originally published by our sister publication Clinical Oncology News

By Clinical Oncology News Staff

The FDA granted accelerated approval to zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC [immunohistochemistry] 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.

The FDA also approved VENTANA PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical